Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers

Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers

Background: Tipifarnib, a farnesyl transferase inhibitor, has shown promising response in the treatment of HRAS-mutant HNSCC in the clinic, and in combination with a PI3K inhibitor in PIK3CA-mutant mouse models; however, the involvement of antitumor immunity in the efficacy of tipifarnib has not yet...

Full description

Saved in:
Bibliographic Details
Main Authors: Dinesh Babu Manikandan, Sankar Jagadeeshan, Sooraj Mathukkada, Raghda Abu Shareb, Manu Prasad, Liju Vijaya Steltar Belsamma, Divyasree Marripati, Noga Erez, Monica Wainer, Amit Geva, Danielle Raviv, Irit Allon, Luc GT Morris, Gloria H Su, Hai Wang, Ari J Rosenberg, Linda Kessler, Francis Burrows, Moshe Elkabets
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Head and neck cancer
HRAS
PI3K
Tipifarnib
Anti-PD1
Alpelisib
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558625000363
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1476558625000363

Similar Items